Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis

مرکز و کتابخانه مطالعات اسلامی به زبان های اروپایی

منو

" Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis "
Ray, Gretchen M.; Rodriguez, Chelsea; Schulman, Samantha; Sarangarm, Preeyaporn; Bardack, Michelle; Bouchonville, Matthew F.

Document Type	:	AL
Record Number	:	928070
Doc. No	:	LA60k8s17c
Language of Document	:	English
Main Entry	:	Ray, Gretchen M.; Rodriguez, Chelsea; Schulman, Samantha; Sarangarm, Preeyaporn; Bardack, Michelle; Bouchonville, Matthew F.
Title & Author	:	Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis [Article]\ Ray, Gretchen M.; Rodriguez, Chelsea; Schulman, Samantha; Sarangarm, Preeyaporn; Bardack, Michelle; Bouchonville, Matthew F.
Title of Periodical	:	Clinical Practice and Cases in Emergency Medicine
Volume/ Issue Number	:	3/2
Date	:	2019
Abstract	:	Empagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emergency department in diabetic ketoacidosis (DKA). This case report details the series of events leading to the diagnosis of drug-induced DKA, which led to a change in the patient’s diagnosis from type 2 diabetes to type 1 diabetes.